| Alizé Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome |
| Scritto da Genetics News From Medical News Today |
 Results from the randomized, double blind and placebo-controlled Phase II trial show significant improvements in hyperphagia-related behavior, a key therapeutic objective in Prader-Willi Syndrome.Fonte: Genetics News From Medical News Today |